dexmedetomidine in colonoscopy

Phase 3

• Conditions: colonoscopy,sedation.; Failed moderate sedation during procedure; T88.52

• Registration Number: IRCT20220706055402N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

The absence of cardiovascular diseases
The absence of kidney or liver failure diseases
absence of drug addiction
absence of contraindications to the use of dexmedetomidine, propofol
people which are classified in class 1 and 2 of the American Society of Anesthesiology (II, I class ASA) are selected.

Exclusion Criteria

Unwillingness of the patient to participate in the study
intestinal perforation during procedure
bleeding of the esophagus or stomach or intestine during the procedure
changing the type of procedure during colonoscopy or requiring surgery during the procedure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total amount of Propofol consumed. Timepoint: From start to end of colonoscopy. Method of measurement: Dose of drug.;Level of sedation. Timepoint: From start to end of colonoscopy. Method of measurement: Ramsay Sedation Scale.;Amount of pain. Timepoint: From start to one hour after colonoscopy. Method of measurement: Visual Analogue Scale.;Amount of Nausea and Vomiting. Timepoint: From start to end of colonoscopy. Method of measurement: Visual Analogue Scale.;Time of recovery. Timepoint: From start to end of colonoscopy. Method of measurement: From end of colonoscopy to full consciousness.;Hemodynamic instability. Timepoint: From start to end of colonoscopy. Method of measurement: Amount of Heart rate, mean arterial pressure and blood oxygen saturation changes.